EGFR gene mutations: A call for global x global views of cancer

Journal of the National Cancer Institute

Volumn 97, Issue 5, 2005, Pages 326-328

  Sellers, William R ^a,b,c   Meyerson, Matthew ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; IMATINIB; MUTANT PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; SEX HORMONE; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; CHRONIC MYELOID LEUKEMIA; EDITORIAL; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN GENOME; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTO ONCOGENE; RECEPTOR GENE; SEQUENCE ANALYSIS; VIRUS ONCOGENE; ADENOCARCINOMA; ANIMAL; ASIAN; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; MUTATION; NEOPLASM; NOTE; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; SEX RATIO;

ADENOCARCINOMA; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC; PREVALENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS;

EID: 14544284557     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji079     Document Type: Editorial

References (19)

1. de The, H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675-84.
2. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-92.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
6. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
10. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
11. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
12. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97: 339-46.
13. Liu W, Innocenti F, Chen P, Das S, Cook EH Jr, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-12.
14. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, et al. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence - first results of an inter-ethnic breast cancer study. J Pathol 2004;203:545-50.
15. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-43.
16. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
17. Vennstrom B, Bishop JM. Isolation and characterization of chicken DNA homologous to the two putative oncogenes of avian erythroblastosis virus. Cell 1982;28:135-43.
18. Frykberg L, Palmieri S, Beug H, Graf T, Hayman MJ, Vennstrom, B. Transforming capacities of avian erythroblastosis virus mutants deleted in the erbA or erbB oncogenes. Cell 1983;32:227-38.
19. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. In press, 2005.